{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T01:30:44Z","timestamp":1778203844741,"version":"3.51.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,3,31]],"date-time":"2016-03-31T00:00:00Z","timestamp":1459382400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100006111","name":"Minist\u00e9rio da Ci\u00eancia, Tecnologia e Ensino Superior","doi-asserted-by":"publisher","award":["PTDC\/BBB-NAN\/1812\/2012"],"award-info":[{"award-number":["PTDC\/BBB-NAN\/1812\/2012"]}],"id":[{"id":"10.13039\/501100006111","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006111","name":"Minist\u00e9rio da Ci\u00eancia, Tecnologia e Ensino Superior","doi-asserted-by":"publisher","award":["UID\/Multi\/04378\/2013"],"award-info":[{"award-number":["UID\/Multi\/04378\/2013"]}],"id":[{"id":"10.13039\/501100006111","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006111","name":"Minist\u00e9rio da Ci\u00eancia, Tecnologia e Ensino Superior","doi-asserted-by":"publisher","award":["UID\/DTP\/04138\/2013"],"award-info":[{"award-number":["UID\/DTP\/04138\/2013"]}],"id":[{"id":"10.13039\/501100006111","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s11095-016-1876-6","type":"journal-article","created":{"date-parts":[[2016,3,31]],"date-time":"2016-03-31T17:45:22Z","timestamp":1459446322000},"page":"1351-1358","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Liposomes as Delivery System of a Sn(IV) Complex for Cancer Therapy"],"prefix":"10.1007","volume":"33","author":[{"given":"M. Lu\u00edsa","family":"Corvo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Soraia","family":"Mendo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Figueiredo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rog\u00e9rio","family":"Gaspar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Larguinho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. F\u00e1tima C.","family":"Guedes da Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro Viana","family":"Baptista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra R","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,3,31]]},"reference":[{"key":"1876_CR1","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10565-010-9178-y","volume":"27","author":"M Varela-Ramirez","year":"2011","unstructured":"Varela-Ramirez M, Costanzo YP, Carrasco KH, Pannell, Aguilera RJ. Cytotoxic effects of two organotin compounds and their mode of inflicting cell death on four mammalian cancer cells. Cell Biol Toxicol. 2011;27:159\u201368. doi: 10.1007\/s10565-010-9178-y .","journal-title":"Cell Biol Toxicol"},{"key":"1876_CR2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/aoc.331","volume":"16","author":"M Gielen","year":"2002","unstructured":"Gielen M. Organotin compounds and their therapeutic potential: a report from the organometallic chemistry department of the free University of Brussels. Appl Organomet Chem. 2002;16:81\u2013494. doi: 10.1002\/aoc.331 .","journal-title":"Appl Organomet Chem"},{"key":"1876_CR3","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ccr.2007.12.026","volume":"253","author":"SK Hadjikakou","year":"2009","unstructured":"Hadjikakou SK, Hadjiliadis N. Antiproliferative and anti-tumor activity of organotin compounds. Coord Chem Rev. 2009;253:235\u201349. doi: 10.1016\/j.ccr.2007.12.026 .","journal-title":"Coord Chem Rev"},{"key":"1876_CR4","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.jorganchem.2005.12.025","volume":"691","author":"L Pellerito","year":"2006","unstructured":"Pellerito L, Nagy L, Pellerito PM, Szorcsik A. Biological activity studies on organotin(IV)n+ complexes and parent compounds. J Organomet Chem. 2006;691:1733\u201347. doi: 10.1016\/j.jorganchem.2005.12.025 .","journal-title":"J Organomet Chem"},{"key":"1876_CR5","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jorganchem.2013.12.019","volume":"760","author":"KT Mahmudov","year":"2014","unstructured":"Mahmudov KT, Guedes da Silva MFC, Kopylovich MN, Fernandes AR, Silva A, Mizar A, et al. Di- and tri-organotin(IV) complexes of arylhydrazones of methylene active compounds and their antiproliferative activity. J Organomet Chem. 2014;760:67\u201373. doi: 10.1016\/j.jorganchem.2013.12.019 .","journal-title":"J Organomet Chem"},{"key":"1876_CR6","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ejmech.2014.07.028","volume":"84","author":"M Sirajuddin","year":"2014","unstructured":"Sirajuddin M, Ali S, McKee V, Sohail M, Pasha H. Potentially bioactive organotin(IV) compounds: synthesis, characterization, in vitro bioactivities and interaction with SS-DNA. Eur J Med Chem. 2014;84:343\u201363. doi: 10.1016\/j.ejmech.2014.07.028 .","journal-title":"Eur J Med Chem"},{"key":"1876_CR7","doi-asserted-by":"crossref","first-page":"833","DOI":"10.3923\/pjbs.2012.833.838","volume":"15","author":"N Awang","year":"2012","unstructured":"Awang N, Kamaludin NF, Hamid A, Mokhtar NW, Rajab NF. Cytotoxicity of triphenyltin(IV) methyl- and ethylisopropyldithiocarbamate compounds in chronic myelogenus leukemia cell line (K-562). Pak J Biol Sci. 2012;15:833\u20138. doi: 10.3923\/pjbs.2012.833.838 .","journal-title":"Pak J Biol Sci"},{"key":"1876_CR8","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.drudis.2009.02.002","volume":"14","author":"A Alama","year":"2009","unstructured":"Alama A, Tasso B, Novelli F, Sparatore F. Organometallic compounds in oncology: implications of novel organotins as antitumor agents. Drug Discov Today. 2009;14:500\u20138. doi: 10.1016\/j.drudis.2009.02.002 .","journal-title":"Drug Discov Today"},{"key":"1876_CR9","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1002\/ejic.200900388","volume":"2009","author":"M Gajewska","year":"2009","unstructured":"Gajewska M, Luzyanin KV, MFC G d S, Li Q, Cui J, Pombeiro AJL. Cyclic trinuclear diorganotin(IV) complexes\u2014the first tin compounds bearing oximehydroxamate ligands: synthesis, structural characterization and high in vitro cytotoxicity. Eur J Inorg Chem. 2009;2009:3765\u20139. doi: 10.1002\/ejic.200900388 .","journal-title":"Eur J Inorg Chem"},{"key":"1876_CR10","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.jorganchem.2005.12.033","volume":"691","author":"S Tabassum","year":"2006","unstructured":"Tabassum S, Pettinari C. Chemical and biotechnological developments in organotin cancer chemotherapy. J Organomet Chem. 2006;691:1761\u20136. doi: 10.1016\/j.jorganchem.2005.12.033 .","journal-title":"J Organomet Chem"},{"key":"1876_CR11","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/aoc.771","volume":"19","author":"M Gielen","year":"2005","unstructured":"Gielen M, Biesemans M, Willem R. Organotin compounds: from kinetics to stereochemistry and antitumour activities. Appl Organomet Chem. 2005;19:440\u201350. doi: 10.1002\/aoc.771 .","journal-title":"Appl Organomet Chem"},{"key":"1876_CR12","doi-asserted-by":"crossref","unstructured":"Pettinari C, Marchetti F. In: Tin chemistry: fundamentals, frontiers, and applications. John Wiley & Sons, ch. 4; 2008. p. 454\u2013468. doi: 10.1002\/9780470758090 .","DOI":"10.1002\/9780470758090"},{"key":"1876_CR13","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1515\/dmdi-2013-0015","volume":"8","author":"A Silva","year":"2013","unstructured":"Silva A, Luis D, Santos S, Silva J, Mendo AS, Coito L, et al. Biological characterization of the antiproliferative potential of Co(II) and Sn(IV) coordination compounds in human cancer cell lines: a comparative proteomic approach. Drug Metabol Drug Interact. 2013;8:167\u201376. doi: 10.1515\/dmdi-2013-0015 .","journal-title":"Drug Metabol Drug Interact"},{"key":"1876_CR14","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1158\/1940-6207.CAPR-10-0006","volume":"4","author":"SS Bansal","year":"2011","unstructured":"Bansal SS, Goel M, Aqil F, Vadhanam MV, Gupta RC. Advanced drug delivery systems of curcumin for cancer chemoprevention. Cancer Prev Res. 2011;4:1158\u201371. doi: 10.1158\/1940-6207.CAPR-10-0006 .","journal-title":"Cancer Prev Res"},{"key":"1876_CR15","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1517\/17425240903427940","volume":"7","author":"T Kaasgaard","year":"2010","unstructured":"Kaasgaard T, Andresen TL. Liposomal cancer therapy: exploiting tumor characteristics. Expert Opin Drug Deliv. 2010;7:225\u201343. doi: 10.1517\/17425240903427940 .","journal-title":"Expert Opin Drug Deliv"},{"key":"1876_CR16","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.tips.2009.08.004","volume":"30","author":"Y Malam","year":"2009","unstructured":"Malam Y, Loizidou M, Seifalian AM. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci. 2009;30:592\u20139. doi: 10.1016\/j.tips.2009.08.004 .","journal-title":"Trends Pharmacol Sci"},{"key":"1876_CR17","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1016\/j.biomaterials.2012.01.057","volume":"33","author":"G Mangiapia","year":"2012","unstructured":"Mangiapia G, D\u2019Errico G, Simeone L, Irace C, Radulescu A, Di Pascale A, et al. Ruthenium-based complex nanocarriers for cancer therapy. Biomaterials. 2012;33:3770\u201382. doi: 10.1016\/j.biomaterials.2012.01.057 .","journal-title":"Biomaterials"},{"key":"1876_CR18","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1021\/bm400104b","volume":"14","author":"G Mangiapia","year":"2013","unstructured":"Mangiapia G, Vitiello G, Irace C, Santamaria R, Colonna A, Angelico R, et al. Anticancer cationic ruthenium nanovetors: from rational molecular design to cellular uptake and bioactivity. Biomacromolecules. 2013;14:2549\u201360. doi: 10.1021\/bm400104b .","journal-title":"Biomacromolecules"},{"key":"1876_CR19","doi-asserted-by":"crossref","first-page":"16697","DOI":"10.1039\/c3dt52320a","volume":"42","author":"D Montesarchio","year":"2013","unstructured":"Montesarchio D, Mangiapia G, Vitiello G, Musumeci D, Irace C, Santamaria R, et al. A new design for nucleolipid-based Ru(III) complexes as anticancer agents. Dalton Trans. 2013;42:16697\u2013708. doi: 10.1039\/c3dt52320a .","journal-title":"Dalton Trans"},{"key":"1876_CR20","doi-asserted-by":"crossref","unstructured":"Lopes SCA, Giuberti CS, Rocha TGR, Ferreira DS, Leite EA, Oliveira MC. Liposomes as Carriers of Anticancer Drugs. In: Rangel L, editor. Cancer treatment\u2014conventional and innovative approaches. Chapter 4. InTech, 2013. doi: 10.5772\/55290 .","DOI":"10.5772\/55290"},{"key":"1876_CR21","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/978-3-319-16555-4_5","volume":"166","author":"DM Charron","year":"2015","unstructured":"Charron DM, Chen J, Zheng G. Theranostic lipid nanoparticles for cancer medicine. Cancer Treat Res. 2015;166:103\u201327. doi: 10.1007\/978-3-319-16555-4_5 .","journal-title":"Cancer Treat Res"},{"key":"1876_CR22","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s13346-015-0218-2","volume":"5","author":"JT Cole","year":"2015","unstructured":"Cole JT, Holland NB. Multifunctional nanoparticles for use in theranostic applications. Drug Deliv Transl Res. 2015;5:295\u2013309. doi: 10.1007\/s13346-015-0218-2 .","journal-title":"Drug Deliv Transl Res"},{"key":"1876_CR23","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S1470-2045(12)70476-X","volume":"13","author":"C Mamot","year":"2012","unstructured":"Mamot C, Ritschard R, Wicki A, Stehle G, Dieterle T, Bubendorf L, et al. Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study. Lancet Oncol. 2012;13:1234\u201341. doi: 10.1016\/S1470-2045(12)70476-X .","journal-title":"Lancet Oncol"},{"key":"1876_CR24","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.plipres.2004.12.001","volume":"44","author":"TL Andresen","year":"2005","unstructured":"Andresen TL, Jensen SS, J\u00f8rgensen K. Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. Prog Lipid Res. 2005;44:68\u201397. doi: 10.1016\/j.plipres.2004.12.001 .","journal-title":"Prog Lipid Res"},{"key":"1876_CR25","doi-asserted-by":"crossref","first-page":"295102","DOI":"10.1088\/0957-4484\/25\/29\/295102","volume":"25","author":"HW Kao","year":"2014","unstructured":"Kao HW, Lin YY, Chen CC, Chi KH, Tien DC, Hsia CC, et al. Biological characterization of cetuximab-conjugated gold nanoparticles in a tumor animal model. Nanotechnology. 2014;25:295102. doi: 10.1088\/0957-4484\/25\/29\/295102 .","journal-title":"Nanotechnology"},{"key":"1876_CR26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0041410","volume":"7","author":"J Lehtinen","year":"2012","unstructured":"Lehtinen J, Raki M, Bergstr\u00f6m KA, Uutela P, Lehtinen K, Hiltunen A, et al. Pre-targeting and direct immunotargeting of liposomal drug carriers to ovarian carcinoma. PLoS One. 2012;7, e41410. doi: 10.1371\/journal.pone.0041410 .","journal-title":"PLoS One"},{"key":"1876_CR27","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1021\/bc9004975","volume":"21","author":"J Lee","year":"2010","unstructured":"Lee J, Choi Y, Kim K, Hong S, Park HY, Lee T, et al. Characterization and cancer cell specific binding properties of anti-EGFR antibody conjugated quantum dots. Bioconjug Chem. 2010;21:940\u20136. doi: 10.1021\/bc9004975 .","journal-title":"Bioconjug Chem"},{"key":"1876_CR28","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00404-010-1389-1","volume":"283","author":"L Hertlein","year":"2011","unstructured":"Hertlein L, Lenhard M, Kirschenhofer A, Kahlert S, Mayr D, Burges A, et al. Cetuximab monotherapy in advanced cervical cancer: a retrospective study with five patients. Arch Gynecol Obstet. 2011;283:109\u201313. doi: 10.1007\/s00404-010-1389-1 .","journal-title":"Arch Gynecol Obstet"},{"key":"1876_CR29","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1468-3083.2009.03446.x","volume":"24","author":"J Ocvirk","year":"2010","unstructured":"Ocvirk J, Cencelj S. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer. J Eur Acad Dermatol Venereol. 2010;24:453\u20139. doi: 10.1111\/j.1468-3083.2009.03446.x .","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1876_CR30","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s00280-009-1090-x","volume":"65","author":"L Liu","year":"2010","unstructured":"Liu L, Cao Y, Tan A, Liao C, Gao F. Cetuximab-based therapy versus non-cetuximab therapy for advanced cancer: a meta-analysis of 17 randomized controlled trials. Cancer Chemother Pharmacol. 2010;65:849\u201361. doi: 10.1007\/s00280-009-1090-x .","journal-title":"Cancer Chemother Pharmacol"},{"key":"1876_CR31","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.2174\/1381612043383467","volume":"10","author":"OP Medina","year":"2004","unstructured":"Medina OP, Zhu Y, Kairemo K. Targeted liposomal drug delivery in cancer. Curr Pharm Des. 2004;10:2981\u20139. doi: 10.2174\/1381612043383467 .","journal-title":"Curr Pharm Des"},{"key":"1876_CR32","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11095-014-1447-7","volume":"32","author":"ML Corvo","year":"2015","unstructured":"Corvo ML, Marinho HS, Marcelino P, Lopes RM, Vale CA, Marques CR, et al. Superoxide dismutase enzymosomes: carrier capacity optimization, in vivo behaviour and therapeutic activity. Pharm Res. 2015;32:91\u2013102. doi: 10.1007\/s11095-014-1447-7 .","journal-title":"Pharm Res"},{"key":"1876_CR33","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s12291-013-0315-2","volume":"29","author":"SE Alavi","year":"2014","unstructured":"Alavi SE, Esfahani MK, Ghassemi S, Akbarzadeh A, Hassanshahi G. In vitro evaluation of the efficacy of liposomal and pegylated liposomal hydroxyurea. Indian J Clin Biochem. 2014;29:84\u20138. doi: 10.1007\/s12291-013-0315-2 .","journal-title":"Indian J Clin Biochem"},{"key":"1876_CR34","first-page":"3320","volume":"58","author":"L Menezes DE de","year":"1998","unstructured":"de Menezes DE L, Pilarski LM, Allen TM. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res. 1998;58:3320\u201330.","journal-title":"Cancer Res"},{"key":"1876_CR35","first-page":"7190","volume":"62","author":"P Sapra","year":"2002","unstructured":"Sapra P, Allen TM. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res. 2002;62:7190\u20134.","journal-title":"Cancer Res"},{"key":"1876_CR36","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/BF02531316","volume":"5","author":"G Rouser","year":"1970","unstructured":"Rouser G, Fkeischer S, Yamamoto A. Two dimensional then layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots. Lipids. 1970;5:494\u20136.","journal-title":"Lipids"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-016-1876-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11095-016-1876-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-016-1876-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T11:37:51Z","timestamp":1718451471000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11095-016-1876-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,31]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["1876"],"URL":"https:\/\/doi.org\/10.1007\/s11095-016-1876-6","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,31]]}}}